

Cambridge University Press  
 978-1-107-43365-6 - Delirium in Critical Care: Second Edition  
 Valerie J. Page and E. Wesley Ely  
 Index  
[More information](#)

## INDEX

- acetylcholine
  - cholinergic deficiency in
    - delirium, 52–3, 55–9
- acetylcholine deficiency, 59–62
- acetylcholinesterase inhibitors, 174
- Activities of Daily Living (ADLs), 100
- acute brain syndrome, 11
- acute confusional state, 6, 11–12, 18
- admission
  - delirium status of patients, 17–18
- adverse effects
  - haloperidol, 165–8
  - pharmacological treatments, 175–6
- adverse outcomes of delirium, 94–108
  - anxiety, 104–6
  - cause of death, 95–8
  - cognitive impairment, 99–100
  - costs of delirium, 107
  - depression, 104–6
  - discharge to long-term care, 104
  - duration of stay in hospital, 106
  - duration of stay in ICU, 106
  - impact on nursing staff, 107
  - independent predictor of
    - mortality, 95–8
  - link with dementia/
    - Alzheimer's disease, 99–100
  - persistent delirium, 95
  - poor functional recovery, 100–4
  - psychological trauma, 104–6
  - PTSD, 104–6
  - severity and duration of
    - delirium, 94–5
  - stress on families and
    - caregivers, 106–7
- aetiology of delirium
  - and motoric subtypes, 39–41
- age
  - and motoric subtype, 35
  - delirium risk in the elderly, 55–9, 72–3
- akathisia
  - side effect of haloperidol, 166
- alcohol withdrawal
  - treatment guidelines, 151
  - use of benzodiazepines, 173–4
- alpha 2 agonists, 172–3
- Alzheimer's disease, 62, 65

Cambridge University Press  
 978-1-107-43365-6 - Delirium in Critical Care: Second Edition  
 Valerie J. Page and E. Wesley Ely

Index

[More information](#)

Index 217

- link with delirium, 99–100
- risk factor for delirium, 55–9
- amino acids
  - role in dementia
    - pathophysiology, 63–5
- anticholinergic drugs
  - precipitating factor for delirium, 85–7
- antipsychotic drugs
  - haloperidol, 160–70
  - history of development, 156–8
  - mode of action, 158–60
  - use in delirium treatment, 155–6
- APACHE (Acute Physiology and Chronic Health Evaluation) score, 20–1
- apolipoprotein E4 (ApoE4)
  - genotype, 65
- arousal aspect of consciousness, 110–11
- attention
  - inability to shift, 112–14
- attention testing, 112–14
- atypical antipsychotics, 170–1
- Barrough, Philip, 6
- Barthel Index, 100
- benzodiazepines
  - and delirium, 53–5, 83–5, 89, 173–4
  - and PTSD, 105
  - use in alcohol withdrawal, 173–4
  - use in ICU patients, 148
- Blessed Dementia Rating Scale, 75
- blood–brain barrier, 62, 64
- brain
  - acute brain failure in delirium, 1–2
  - adverse outcomes related to delirium, 2–3
  - clinical monitoring, 110–11
  - final common neural pathway theory, 46
  - monitoring brain function, 2
  - risk factors for delirium, 55–9
- brain insults
  - role in delirium
    - pathophysiology, 47
- cardiac surgery patients, 64
  - incidence of delirium, 24
  - risk factors for delirium, 90–1
- caregivers
  - stress on, 106–7
- case studies
  - delirium diagnosed as dementia, 75–6
  - diagnosis of terminal delirium, 198–9
  - duration of delirium, 22–4
  - identify and treat the cause, 154–5
  - importance of patient history, 154–5, 198–9
  - mental capacity, 183–4
  - motoric subtypes of delirium, 30–4

## 218 Index

- case studies (*cont.*)
  - multiple precipitating factors, 154–5
  - need for adequate pain relief, 146–8
  - need for delirium screening, 109
  - patient's delirium experience, xi–xvi
  - posterior cerebral artery infarction, 48–9
  - use of physical restraints, 186–7
  - vulnerability to delirium, 82
- catechol-*O*-methyltransferase (COMT), 65
- Celsus, 3–5
- cerebral blood flow, 52
- chemical restraints, 187–9
  - alternatives to, 189
- chlordiazepoxide, 174
- chlorpromazine, 156–8
- cholinergic deficiency in delirium, 52–3, 55
- cirrhotic patients, 55
- classification systems
  - DSM-IV, 7–9
  - ICD-10, 7
- clinical monitoring of the brain, 110–11
  - arousal, 110–11
  - cognition, 110–11
  - level of consciousness, 110–11
  - mental status, 110–11
- clonidine, 150, 172
- clozapine, 158, 170
- CNS dysfunction, 59–62
- cognition aspect of
  - consciousness, 110–11
- cognitive decline risk factor for delirium, 72–3, 75–6
- cognitive failure, 191
- cognitive impairment (pre-existing)
  - risk factor for delirium, 55–9
- cognitive outcomes with delirium, 99–100
- cognitive reserve, 76–7
- Cognitive Test for Delirium, 116
- coma/*koma*, 12
- Confusion Assessment Method (CAM), 119–21
- Confusion Assessment Method for the ICU (CAM-ICU), 18–22, 36, 116, 121–4, 126–7
- confusion mentale* (France), 12
- consciousness
  - arousal and cognition, 110–11
  - dysfunction in delirium, 5–6
- cortisol
  - role in delirium pathophysiology, 63
- costs of delirium, 107
- C-reactive protein, 59
- CT scan (computed tomography scan), 48
- cytokine production in infection, 59–62
- dantrolene, 168
- De Medicina*, 3–5
- definitions of delirium

- acute brain failure, 1–2
- historical descriptions, 3–7
- dehydration risk factor for
  - delirium, 73
- delirio* (Italy), 12
- delirium
  - as acute brain failure, 1–2
  - medical emergency, 2–3
  - responsibility for research, 22
- delirium in ICU
  - education about screening, 203–5
  - questions still to be answered, 202
  - what we do know, 202
  - what we don't know, 202
- delirium tremens, 12
  - treatment guidelines, 151
- dementia
  - and delirium, 55–9
  - delirium mistaken for, 75–6
  - education level risk factor, 76–7
  - link with delirium, 99–100
  - with delirium, 52
  - wrongly applied diagnosis, 75–6
- deprivation of liberty, 182
- detection rate for delirium, 15–17
- dexmedetomidine, 149, 172–3
- diagnosing delirium in critical care, 109–37
  - attention testing, 112–14
  - awake responsive patient, 132
  - awake unresponsive patient, 132
  - clinical monitoring of the brain, 110–11
  - clinical screening tools, 115–31
  - Cognitive Test for Delirium, 116
  - comatose unresponsive patient, 131
  - comparing CAM-ICU and ICDSC, 126–7
  - Confusion Assessment Method (CAM), 119–21
  - Confusion Assessment Method for the ICU (CAM-ICU), 116, 121–4, 126–7
  - constraints on delirium screening, 136–7
  - developing a screening tool for ICU, 116–17
  - implementing delirium screening, 135–7
  - importance of screening, 109
  - inattentive responsive patient, 133–4
  - Intensive Care Delirium Screening Checklist (ICDSC), 116, 124–7
  - mental status, 112–14
  - Mini Mental State Examination (MMSE), 117
  - Montreal Cognitive Assessment, 119
  - Neelon and Champagne (NEECHAM) scale, 117, 127
  - negative screening in hallucinating patient, 134–5
  - Nursing Delirium Scale (Nu-DESC), 117, 131

## 220 Index

- diagnosing delirium in critical care (*cont.*)
  - sedation scores, 112
  - variety of delirium screening tools, 116
  - when we are unable to assess, 134
- diagnosis of delirium, 27–43
  - aetiology and motoric subtype, 39–41
  - difficulty of detection, 28
  - hypoactive delirium, 28
  - importance in palliative care, 35
  - importance of patient history, 75–6
  - low rates of detection, 27
  - motoric subtypes, 28–42
  - prevalence of motoric subtypes, 35
  - psychomotor behaviour, 30–4
  - psychotic symptoms, 41
  - quiet, lethargic patient, 28
  - subsyndromal delirium, 42–3
  - wrong diagnosis of dementia, 75–6
- diagnostic criteria for delirium
  - DSM-IV-TR, 7–9
  - ICD-10, 7
- diazepam, 174
- digoxin, 86
- discharge to home or nursing home, 104
- donepezil, 174
- dopamine
  - as precipitating factor in delirium, 87
  - excess in delirium, 52–3
  - production, 64
- drugs
  - precipitating factors for delirium, 83–7
- DSM-IV-TR (Diagnostic and Statistical Manual of Mental Disorders, text revision)
  - criteria for delirium, 7–9
- duration and severity of delirium, 94–5
- duration of delirium, 22–4
- education
  - about screening for delirium, 203–5
  - publicizing delirium, 206–7
  - staff education about delirium, 145
- education level
  - and cognitive reserve, 76–7
  - risk factor in delirium, 76–7
  - risk factor in dementia, 76–7
- elderly people
  - risk of delirium, 55–9
- electroencephalography (EEG), 51–2
- end-of-life care, 191–201
  - communication with relatives, 198–9
  - distress caused by delirium, 196–7
  - importance of patient documentation, 198–9
  - importance of treating delirium, 191–2

- incidence of delirium, 191–2
- palliative sedation, 199–200
- referral for uncontrolled symptoms, 193–5
- reversible delirium, 192
- when to call in the experts, 193–5, *see also* palliative care.
- environment
  - risk factors for delirium, 87–8
- European Association for Palliative Care, 199–200
- European Delirium Association, 206–7
- exercise
  - protective effect for delirium, 89
- families
  - stress on, 106–7
- fentanyl, 85
- final common neural pathway theory, 46
- flumazenil, 55
- France
  - terminology for delirium, 12
- functional recovery and delirium, 100–4
- furosemide, 86
- future developments, 202–7
  - education about screening for delirium, 203–5
  - pharmacological treatments, 206
  - publicizing delirium, 206–7
  - questions still to be answered, 202
- research collaboration, 206–7
- research priorities, 205–6
- sedation techniques, 206
- GABA ( $\gamma$ -aminobutyric acid)
  - activity in delirium, 53–5
- genetic factors in delirium, 65–6
- Glasgow Coma Score, 25, 89
- glucocorticoids and the stress response, 63
- haloperidol, 160–70
  - adverse effects, 165–8
  - akathisia side effect, 166
  - discovery of, 157
  - dosage for delirious patients, 163–4
  - extrapyramidal side effects, 165
  - mode of action, 158–62
  - neuroleptic malignant syndrome side effect, 166–8
  - properties, 158–60
  - reasons for use in delirium, 162–3
  - risks associated with, 165–8
  - routes of administration, 160–2
  - study of delirium outcomes, 168–70
  - torsades de pointes side effect, 165
  - use in alcohol withdrawal, 151
- hepatic encephalopathy, 11, 55, 65
- Hippocrates, 3–7

## 222 Index

- historical descriptions of
  - delirium, 3–7
- hospital
  - duration of stay, 106
- Hospital Elder Life Program (HELP), 142
- hospital environment
  - risk factors for delirium, 87–8
- hyperactive delirium subtype,
  - 30–4
  - outcomes, 35
  - prevalence of, 35
- hypoactive delirium subtype, 28,
  - 30–4
  - outcomes, 35
  - prevalence of, 35
- hypoxia
  - role in delirium, 47
- ICD-10 (International Classification of Diseases)
  - criteria for delirium, 7
- ICD-10-DR (diagnostic criteria for clinical research), 12
- ICU psychosis, 9
- ICU syndrome, 11
- immobilization
  - risk factor for delirium, 65–6, 73
- immune response to infection, 59–62
- immune system
  - role in delirium, 65–6
- inattention testing, 112–14
- incidence of delirium, 14–15
  - cardiac surgery patients, 24
- delirium status on admission, 17–18
- detection rate, 15–17
- palliative care patients, 25
- special patient groups, 24–5
- trauma patients, 24–5
- variations between screening tools, 18–22
- variations between studies, 17
- inflammatory response, 46–7, 59–62
- Informant Questionnaire on Cognitive Decline in the Elderly, 75
- Inouye, Sharon, 16, 77–83, 139–41
- insulin-like growth factor 1 (IGF-1), 65
- Intensive Care Delirium Screening Checklist (ICDSC), 18–22, 116, 124–7
- interleukin 8, 59
- isosorbide dinitrate, 86
- Italy
  - terminology for delirium, 12
- Jackson, John Hughlings, 5
- Janssen, Paul, 157
- Katz Index, 100
- ketamine, 148
- koma/coma, 12
- lipopolysaccharide, 61
- Lipowski, Zbigniew J., 6, 12, 28, 42
- lorazepam and delirium, 83–4

Cambridge University Press  
 978-1-107-43365-6 - Delirium in Critical Care: Second Edition  
 Valerie J. Page and E. Wesley Ely

Index

[More information](#)

Index 223

- magnetic resonance imaging (MRI), 49
- mechanisms of delirium. *see* pathophysiology
- medical emergency
  - delirium as, 2–3
- melatonin, 89
- mental capacity, 180–90
  - and use of restraints, 180–2
  - assessment, 183–4
  - deprivation of liberty, 182
  - lack of capacity, 183–4
  - protecting vulnerable patients, 183–4
- Mental Capacity Act (UK), 181, 185
- mental status, 112–14
- meperidine and delirium, 85
- metabolic derangements
  - role in delirium, 47
- metabolic encephalopathy, 11
- microglial activation, 61
- midazolam and delirium, 83–4, 90
- Mini Mental State Examination (MMSE), 90, 117
- mixed delirium subtype, 30–4
- mobilization of patients, 145–6
- Montreal Cognitive Assessment, 119
- morphine and delirium, 85
- mortality associated with
  - delirium, 95–8
- motoric subtypes of delirium, 3, 28–42
  - and aetiology, 39–41
  - and outcome, 42
- case studies, 30–4
- definition of subtypes, 38–9
- hyperactive subtype, 30–4
- hypoactive subtype, 30–4
- incidence in critical care, 36–8
- mixed delirium subtype, 30–4
- prevalence of, 35
- psychotic symptoms, 41
- Richmond Agitation-Sedation Scale (RASS) definitions, 36–8
- subtype classification tools, 38–9
- multiple organ failure, 59–62
- Multiple Organ Failure Scale, 90
- multiple sclerosis, 62
- Neelon and Champagne (NEECHAM) scale, 117, 127
- neuroimaging studies
  - pathophysiology of delirium, 48–9
- neuroleptic malignant syndrome
  - side effect of haloperidol, 166–8
- neuronal ageing hypothesis, 46–7
- neurotransmitter imbalances in
  - delirium, 46–7, 52–5, 63–5
  - genetic factors, 65–6
- norepinephrine
  - production, 64
  - role in delirium, 52–3
- Nursing Delirium Scale (Nu-DESC), 117, 131



## 224 Index

- nursing staff
  - stress and delirious patients, 107
- olanzapine, 170–1
- opioid drugs
  - and delirium, 83–5, 89
- outcome
  - adverse effects of delirium, 2–3
  - and delirium motoric subtype, 35, 42
  - poor prognosis of delirium, 6–7
- oxidative stress, 46–7
  - role in delirium, 47
- pain
  - risk factor for delirium, 85
- pain relief
  - role in prevention of delirium, 146–8
- palliative care
  - importance of diagnosis of delirium, 35
  - incidence of delirium, 25, *see also* end-of-life care.
- palliative sedation, 199–200
- Parkinson's disease, 179
- pathophysiology, 45–67
  - brain vulnerability factors, 55–9
  - cascading effect in the brain, 46–7
  - central nervous system dysfunction, 59–62
  - cerebral blood flow, 52
  - cholinergic deficiency, 52–3, 55–9
  - cytokine production in infection, 59–62
  - direct brain insults, 47
  - dopamine excess, 52–3
  - effects of acetylcholine deficiency, 59–62
  - effects of immobilization, 65–6
  - electroencephalography (EEG), 51–2
  - energy deprivation in the brain, 47
  - final common neural pathway theory, 46
  - GABA ( $\gamma$ -aminobutyric acid) activity, 53–5
  - genetic factors, 65–6
  - glucocorticoids and the stress response, 63
  - hypoxia, 47
  - immune response to infection, 59–62
  - immunological effects, 65–6
  - inflammatory response, 46–7, 59–62
  - metabolic derangements, 47
  - multiple organ failure, 59–62
  - neuroimaging studies, 47, 48–9
  - neuronal ageing hypothesis, 46–7
  - neurotransmitter imbalances, 46–7, 52–5, 63–6
  - oxidative stress, 46–7

Cambridge University Press  
 978-1-107-43365-6 - Delirium in Critical Care: Second Edition  
 Valerie J. Page and E. Wesley Ely

Index

[More information](#)

Index 225

- range of theories, 45
- risk factors for delirium, 55–9
- role of amino acids, 63–5
- role of cortisol, 63
- role of norepinephrine, 52–3
- role of serotonin  
     (5-hydroxytryptamine), 52–3
- search for a serum biomarker,  
     55
- septic brain, 59–62
- serum anticholinergic activity  
     (SAA), 55
- spreading depression effect,  
     46–7
- stress response and  
     glucocorticoids, 63
- patient's delirium experience,  
     xi–xvi
- persistent delirium, 91, 95
- pharmacological treatment,  
     155–76
- acetylcholinesterase inhibitors,  
     174
- adverse effects, 175–6
- alpha 2 agonists, 172–3
- atypical antipsychotics, 170–1
- benzodiazepines and delirium,  
     83–4, 173–4
- clonidine, 172
- dexmedetomidine, 172–3
- donepezil, 174
- drugs as precipitating factor in  
     delirium, 83–7
- extrapyramidal side effects,  
     165, 170–1
- future developments, 206
- haloperidol, 160–70
- history of antipsychotic drugs,  
     156–8
- lack of studies, 176
- mode of action of  
     antipsychotics, 158–60
- olanzapine, 170–1
- ondansetron, 175
- opioid drugs and delirium,  
     83–5
- propofol, 173
- risperidone, 170–1
- sodium valproate, 174–5
- use of antipsychotic drugs,  
     155–6
- phenylalanine, 63–4
- physical restraints, 87–8, 91–2,  
     186–7
- alternatives to, 189
- and PTSD, 105
- posterior cerebral artery  
     infarction, 48–9
- precipitating/predisposing  
     factors for delirium, 80–92
- prevalence of delirium, 17–18
- preventative approach to  
     delirium, 91–2
- prevention of delirium, 139–51
- alcohol withdrawal, 151
- control of sedation, 148–50
- delirium care bundle, 143
- early mobilization of patients,  
     145–6
- education of staff, 145
- Hospital Elder Life Program  
     (HELP), 142

Cambridge University Press  
 978-1-107-43365-6 - Delirium in Critical Care: Second Edition  
 Valerie J. Page and E. Wesley Ely

Index

[More information](#)

## 226 Index

- prevention of delirium (*cont.*)
  - pain relief, 146–8
  - specialized or targeted care, 143–4
  - studies, 139–41
  - use drugs that prevent delirium, 150
  - ward dedicated to elderly care, 143–4
- prochlorperazine, 85
- Procopius, 5
- prognosis for delirium, 6–7
- promethazine, 157
- propofol, 148, 173
- psychiatrist
  - role in delirium treatment, 176–7
- psychological outcomes with delirium, 104–6
- psychotic symptoms
  - and motoric subtypes, 41
- PTSD (post-traumatic stress disorder), 104–6
- publicizing delirium
  - research collaboration, 206–7
- quetiapine, 170
- Ramsay scale, 148
- remifentanyl, 149
- research
  - collaboration, 206–7
  - future priorities, 205–6
  - responsibility for delirium research, 22
  - types of delirium studies, 69–70
- restraints
  - alternatives to, 189
  - and mental capacity, 180–2
  - chemical, 184–5, 187–9
  - deprivation of liberty, 182
  - legal and ethical issues, 184–5
  - physical, 88, 91–2, 105, 186–7, 188–9
- Richmond Agitation-Sedation Scale (RASS), 36–8, 112, 148
- risk factors for delirium, 68–92
  - Alzheimer's disease, 55–9
  - blood transfusions, 89–90
  - cardiac surgery patients, 90–1
  - cognitive decline, 72–3, 75–6
  - cognitive impairment (pre-existing), 55–9
  - degree of vulnerability, 82
  - dehydration, 73
  - dementia, 55–9
  - drugs as precipitating factors, 83–7
  - elderly people, 55–9
  - hospital environment, 87–8
  - hospitalized patients, 77–80
  - immobilization, 65–6, 73
  - lack of education, 76–7
  - lack of environmental orientation cues, 87–8
  - lack of exercise, 89
  - need to screen critically ill patients, 69
  - older age, 72–3
  - pain, 85
  - preventative approach, 91–2
  - sensory deprivation, 87–8

Cambridge University Press  
 978-1-107-43365-6 - Delirium in Critical Care: Second Edition  
 Valerie J. Page and E. Wesley Ely

Index

[More information](#)

Index 227

- sleep problems, 88–9
- statistics from delirium studies, 70–2
- trauma patients, 89–90
- types of clinical studies, 69–70
- visual or hearing deficit, 87–8
- risk model in hospitalized patients, 77–80
- risperidone, 170–1
- rivastigmine, 174
- screening for delirium
  - importance of, 109
- screening patients
  - awake responsive patient, 132
  - awake unresponsive patient, 132
  - comatose unresponsive patient, 131
  - constraints on delirium screening, 136–7
  - implementing delirium screening, 135–7
  - inattentive responsive patient, 133–4
  - negative screening in
    - hallucinating patient, 134–5
  - when we are unable to assess, 134
- screening programmes
  - education about screening, 203–5
- screening tools, 18–22, 115–31
  - comparing CAM-ICU and ICDSC, 126–7
  - developing a screening tool for ICU, 116–17
  - variations in incidence rates, 18–22
  - variety of delirium assessment tools, 116
- sedation
  - palliative, 199–200
- sedation control, 148–50
- sedation scores, 112
- sedation techniques
  - future developments, 206
- septic brain, 59–62
- septic encephalopathy, 11, 59
- serotonin (5-hydroxytryptamine), 63–5
  - role in delirium, 52–3
- serum anticholinergic activity (SAA), 55
- severity and duration of delirium, 94–5
- sleep problems
  - and delirium, 88–9
- sodium valproate, 174–5
- somatostatin, 65
- staff
  - education about delirium, 145
- statistics from delirium studies, 70–2
- stato confusionale acuto* (Italy), 12
- stemetil, 85
- stress response and
  - glucocorticoids, 63
- stroke, 62
- subsyndromal delirium, 42–3

Cambridge University Press  
 978-1-107-43365-6 - Delirium in Critical Care: Second Edition  
 Valerie J. Page and E. Wesley Ely  
 Index  
[More information](#)

## 228 Index

- terminal agitation, 191
- terminal restlessness, 191
- terminology for delirium
  - France, 12
  - Italy, 12
  - lack of standardization, 9–12
  - terms used in critical care, 9–12
- theophylline, 86
- thiamine, 174
- torsades de pointes
  - side effect of haloperidol, 165
- toxic confusional state, 11
- trauma patients
  - incidence of delirium, 24–5
  - risk factors for delirium, 89–90
- treatment of delirium in critical care, 153–79
  - basic steps, 177
  - hyperactive delirium, 177–8
  - hypoactive delirium, 178–9
  - identify and treat the cause, 153–5
  - importance of patient history, 153–5
  - multiple precipitating factors, 153–5
  - pharmacological treatment, 155–76
  - role of the psychiatrist, 176–7
- tryptophan availability
  - and serotonin production, 63–5
- tumour necrosis factor (TNF), 61
- tyrosine, 63–4
- valine, 64
- vulnerability to delirium, 82
- Wernicke's encephalopathy, 174